The FDA on Nov. 13, 2026, approved obinutuzumab (Gazyva) as the first drug specifically for adults with primary membranous nephropathy. In the pivotal trial, 36% of patients reached complete remission of proteinuria at two years, versus 6% on tacrolimus, the agency said.
Until now, doctors treated this autoimmune kidney disease with drugs approved for other conditions, used off-label. Genentech estimates it affects more than 96,000 people in the U.S. and that up to 30% develop kidney failure within 10 years. For students it is a classic nephrotic syndrome topic with a new treatment answer; for residents on nephrology and medicine services, it is the first FDA-labeled option to weigh against off-label regimens.
A 31-point gap in complete remission at week 104
The approval rests on MAJESTY, a phase 3, randomized, open-label trial that assigned 142 adults to intravenous obinutuzumab or oral tacrolimus for a 104-week main study period, according to the FDA. The FDA notes tacrolimus is sometimes used off-label for the disease.
Complete remission meant a urine protein-to-creatinine ratio of 0.3 g/g or lower with a stable estimated glomerular filtration rate (eGFR), without rescue therapy or treatment failure. In the New England Journal of Medicine report of the trial, 26 of 71 patients on obinutuzumab and 4 of 70 on tacrolimus met that bar: 37% vs 6% after imputation for missing data, an adjusted difference of 31 percentage points (95% CI, 18 to 44). The FDA's figure is 36%.
Two key secondary endpoints, complete or partial remission at week 104 and complete remission at week 76, also favored obinutuzumab, the NEJM paper reported. The FDA gave the application Breakthrough Therapy, Orphan Drug and Priority Review designations.
Gazyva was already approved for certain cancers, active lupus nephritis and childhood-onset idiopathic nephrotic syndrome, the FDA said, so this is its third kidney indication.
The catch: no proof yet that it slows loss of kidney function
Remission is not the same as protected kidneys. MAJESTY's next key endpoint, a sustained eGFR drop of at least 30%, showed no significant difference between groups, so later endpoints in the testing hierarchy, including fatigue scores, were not formally tested, according to the NEJM paper.
Other limits are worth knowing before you quote the trial:
- Open label: patients and doctors knew which drug was given.
- The comparator was tacrolimus, not rituximab. Rituximab is one of the main guideline options (see below), so MAJESTY does not show obinutuzumab beats it.
- Industry funding: F. Hoffmann-La Roche funded the trial, and six of the listed authors have Roche or Genentech affiliations.
Rates of serious side effects were close between arms. Grade 3 or higher adverse events occurred in 22% of obinutuzumab patients and 19% on tacrolimus; serious adverse events in 17% and 14%. Infections ran at 61 vs 57 per 100 patient-years, and one patient in each group died during escape therapy. The label carries boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy (PML), and the most common side effects were infusion-related reactions and upper respiratory infections, the FDA said.
What to remember for boards and rounds
- The antibody clue: about 70% of patients with primary membranous nephropathy have anti-PLA2R antibodies, and under the 2021 KDIGO guideline a typical nephrotic presentation with positive antibodies can be diagnosed without a biopsy, according to a 2022 Journal of Nephrology review of the guideline.
- The pre-approval treatment menu: that review summarizes KDIGO 2021 as supportive therapy, rituximab or a calcineurin inhibitor for moderate-risk patients, and rituximab, six months of cyclophosphamide plus glucocorticoids, or a calcineurin inhibitor plus rituximab for high-risk patients. Question banks written before Nov. 13 will not reflect the new label.
- The drug class: obinutuzumab is a type II anti-CD20 monoclonal antibody, per the NEJM report. When a question pairs it with a hepatitis B history or new neurologic deficits, think of its two boxed warnings: hepatitis B reactivation and PML.
- The trial-reading question to ask: "Better than what, on which endpoint?" MAJESTY beat tacrolimus on remission at two years. It did not test rituximab, and it did not show a difference in eGFR decline.
Practice-style reviews of kidney and medicine topics are in MedRise Shelf Prep, and our last FDA story covered asundexian for stroke prevention. More resources are on the students and residents pages.
What to watch next
The open questions are whether guideline writers move obinutuzumab ahead of rituximab without a head-to-head trial, and whether longer follow-up shows the remission advantage translates into fewer patients reaching kidney failure. Dosing details are in the full prescribing information, which the FDA release does not summarize.
Membranous nephropathy finally has a drug with its name on the label. The next test is whether more remissions mean kidneys that last longer.
Sources: FDA, FDA approves first drug to treat adults with primary membranous nephropathy, Nov. 13, 2026; Fervenza FC, et al. Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy. N Engl J Med. 2026;395(10):959-971 (via PubMed); Genentech, Phase III MAJESTY results, Feb. 15, 2026; Stai S, et al. From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines. J Nephrol. 2023;36(2):551-561.
MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.
